Upadacitinib: A Convenient and Effective Alternative Treatment for Spondyloarthritis

By HEOR Staff Writer

February 3, 2023

Treatment guidelines for adults with active non-radiographic axial spondyloarthritis recommend the use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Tumor Necrosis Factor-alpha (TNF-alpha) inhibitors. If these first-line treatments don’t work or aren’t suitable, doctors may consider secukinumab or ixekizumab (IL-17 inhibitors). Clinical trials show that upadacitinib, an oral Janus Kinase (JAK) inhibitor, can reduce symptoms and improve the quality of life in Spondyloarthritis (SpA) patients. This effectiveness rivals that of biologics. Clinicians use the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score and/or Visual Analogue Scale (VAS) score to measure this. A cost comparison shows that upadacitinib costs about the same and provides similar health benefits as secukinumab and ixekizumab.

The update suggests considering upadacitinib as an alternative to the National Institute for Health and Care Excellence (NICE) recommended Interleukin (IL)-17 inhibitors. This is especially important if conventional therapy doesn’t control the condition well enough or if TNF-alpha inhibitors aren’t suitable or effective.

Clinical and patient experts highlighted the convenience of upadacitinib over IL-17 inhibitors owing to its oral administration.

Reference url

Recent Posts

Enhertu Breast Cancer Treatment Gains FDA Approval in Neoadjuvant and Adjuvant Settings

By João L. Carapinha

May 18, 2026

Enhertu breast cancer treatment has secured FDA approval for neoadjuvant use in adults with HER2-positive Stage II or III disease before surgery, followed by taxane plus trastuzumab and pertuzumab, and for adjuvant therapy in patients with residual invasive disease after prior trastuzumab-based r...
Pharmaceutical Onshoring Agreements: Navigating Tariff Relief and National Security Policies

By João L. Carapinha

The US Bureau of Industry and Security published formal procedures enabling manufacturers of patented pharmaceutical products to apply for company-specific pharmaceutical onshoring agreements with the Department of Commerce. These agreements allow qualifying firms to secure a reduced Section 232 ...
Dynamic Risk Stratification in Thromboembolism Prevention for Cancer Patients

By João L. Carapinha

Dynamic risk stratification enables more precise forecasting of venous thromboembolism risk in cancer patients by continuously updating predictions as new clinical data emerge. A transformer-based deep learning model was developed using longitudinal electronic health records from the U.S. Veteran...